This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
WuXi XDC uses a specialty Light-Protect-Label from Schreiner MediPharm, a leading developer and manufacturer of innovative functional labels for the healthcare industry. For a current clinical trial of a novel antibody drug conjugate (ADC), a label with light protection was needed that at the same time blinds the drug. The light protection label from Schreiner MediPharm makes this possible: It reliably protects the light-sensitive active ingredient while enabling inspection of the vial content in the original color and neutralizing the investigational drug.
WuXi XDC is a leading contract research, development, and manufacturing organization (CRDMO) headquartered in China with a focus on the global ADC and bioconjugate market. To support a biotech company in a clinical trial for an ADC drug, WuXi XDC required a reliable label solution. The light-sensitive active ingredient is filled into vials as a lyophilized powder and must be effectively protected against external influences. WuXi XDC found the most suitable solution through the cooperation with Schreiner MediPharm by implementing a Light-Protect-Label that perfectly met the specific customer requirements.
he opaque label completely wraps around the container and offers optimal light protection.Schreiner MediPharm
The innovative label-integrated light protection solution from Schreiner MediPharm was customized to suit the specific application and respective container. Schreiner MediPharm can draw upon its extensive expertise in materials, adhesives, and printing techniques, as well as comprehensive tests of light protection properties. Hence WuXi XDC benefits from an efficient, multifunctional solution combining protection of the light-sensitive active ingredient with reliable blinding as part of a clinical trial. This optimizes processes, accelerates clinical trial workflow, and supports product and patient safety.
The light protection solution from Schreiner MediPharm proves to be particularly forward-looking because it is well-suited for use in antibody drug conjugates like the one in this trial. ADCs are an important innovation in cancer therapy. Through targeted delivery of drugs into specific tumor cells, they enable gentler and more effective treatment compared to conventional chemotherapies. This technology acts directly on the cancer cell, largely sparing healthy cells and minimizing side effects.
